Sickle cell bone disease and response to intravenous bisphosphonates in children
Chelsey Grimbly(University of Alberta), Leanne M. Ward(Children's Hospital of Eastern Ontario), Marie‐Eve Robinson(University of Ottawa), Rose Girgis(University of Alberta Hospital), R. Todd Alexander(University of Alberta), Nathalie Alos(Centre Hospitalier Universitaire Sainte-Justine), Patricia Diaz Escagedo(Centre Hospitalier Universitaire Sainte-Justine), Jacob L. Jaremko(University of Alberta), Marika Pagé, Victor N. Konji, Ewurabena Simpson(University of Ottawa), Yves Pastore(Centre Hospitalier Universitaire Sainte-Justine), Aisha Bruce(University of Alberta), Maya Scharke(Children's Hospital of Eastern Ontario)
Cited by 20
Related Papers
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial
|The Lancet|2019|375
Calcium and phosphate homeostasis: Concerted interplay of new regulators
|Annals of Medicine|2008|262
Traditional and emerging roles for the SLC9 Na+/H+ exchangers
|Pflügers Archiv - European Journal of Physiology|2013|187